K.J. Harrison & Partners Inc lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 18.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,825 shares of the company’s stock after selling 2,208 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Johnson & Johnson were worth $1,368,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of JNJ. Thoroughbred Financial Services LLC boosted its stake in shares of Johnson & Johnson by 14,147.0% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after purchasing an additional 3,986,071 shares during the last quarter. Nordea Investment Management AB boosted its stake in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock worth $1,217,494,000 after acquiring an additional 1,079,751 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its stake in Johnson & Johnson by 152.1% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 1,083,996 shares of the company’s stock worth $122,372,000 after acquiring an additional 654,085 shares during the last quarter. Royal London Asset Management Ltd. boosted its stake in Johnson & Johnson by 53.2% during the 4th quarter. Royal London Asset Management Ltd. now owns 1,869,313 shares of the company’s stock worth $199,471,000 after acquiring an additional 648,775 shares during the last quarter. Finally, Jensen Investment Management Inc. boosted its stake in Johnson & Johnson by 23.6% during the 2nd quarter. Jensen Investment Management Inc. now owns 2,903,660 shares of the company’s stock worth $404,422,000 after acquiring an additional 554,783 shares during the last quarter. 67.23% of the stock is currently owned by hedge funds and other institutional investors.
Shares of JNJ stock opened at $128.07 on Wednesday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The company has a market capitalization of $337.10 billion, a P/E ratio of 15.66, a price-to-earnings-growth ratio of 2.16 and a beta of 0.69. The company’s 50 day moving average price is $131.66 and its two-hundred day moving average price is $136.44. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.97%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.
In related news, Director Marillyn A. Hewson bought 3,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $419,040. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.23% of the company’s stock.
Several research analysts recently weighed in on JNJ shares. Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Wells Fargo & Co reissued an “outperform” rating and set a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Morgan Stanley reissued an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Barclays started coverage on shares of Johnson & Johnson in a research note on Friday, June 21st. They set a “hold” rating and a $140.00 price objective on the stock. Finally, Bank of America reissued a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $150.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: What is the market perform rating?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.